Crossmark

The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review

Crossref DOI link: https://doi.org/10.1186/s13643-019-1235-x

Published Online: 2019-12-11

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Van den Nest, Miriam http://orcid.org/0000-0003-2653-3473
Glechner, Anna

Gold, Maria

Gartlehner, Gerald
Funding

Funding for this research was provided by:

Department of Evidence-based Medicine and Clinical Epidemiology, Danube University Krems, Austria
License Information

Text and Data Mining valid from 2019-12-01

Version of Record valid from 2019-12-11
More Information

Article History

Received: 21 January 2019

Accepted: 14 November 2019

First Online: 11 December 2019

Competing interests

: All authors declare that they have no competing interests.

Document is current

Any future updates will be listed below